Trade Names:Aller-Chlor- Tablets 4 mg- Syrup 2 mg per 5 mL
Trade Names:Allergy- Tablets 4 mg
Trade Names:Allergy Relief- Tablets 4 mg
Trade Names:Chlor-Trimeton- Tablets 4 mg
Trade Names:Chlor-Trimeton Allergy 8 Hour- Tablets, extended-release 8 mg
Trade Names:Chlor-Trimeton Allergy 12 Hour- Tablets, extended-release 12 mg
Trade Names:Chlorpheniramine Maleate- Capsules, sustained-release 8 mg- Capsules, sustained-release 12 mg
Trade Names:Chlorpheniramine Maleate- Tablets 4 mgChlor-Tripolon (Canada)
Competitively antagonizes histamine at H 1 receptor sites.
72% protein bound.
Metabolized predominantly in the liver, but also in the lung and kidneys.
Renally eliminated, mostly as metabolites within 24 h.
Temporary relief of sneezing, itchy, watery eyes, itchy nose or throat, and runny nose caused by hay fever (allergic rhinitis), or other respiratory allergies.
Hypersensitivity to antihistamines; narrow-angle glaucoma; stenosing peptic ulcer; symptomatic prostatic hypertrophy; asthmatic attack; bladder neck obstruction; pyloroduodenal obstruction; MAO therapy; use in newborn or premature infants and in breast-feeding mothers.
PO 4 mg every 4 to 6 h (max, 24 mg/day).Children 6 to younger than 12 yr of age
PO 2 mg every 4 to 6 h (max, 12 mg/day).Children younger than 5 yr of age
PO As recommended by health care provider.Extended-release tabletsAdults and children 12 yr of age and older
PO 8 mg every 8 to 12 h or 12 mg every 12 h (max, 24 mg/day).Extended-release capsulesAdults and children 12 yr of age and older
PO 8 or 12 mg in the morning and evening (max, 24 mg/day).
Store all dose forms at controlled room temperature (59° to 86°F).
May cause additive CNS depressant effects.MAOIs
May increase anticholinergic effects of chlorpheniramine.Ototoxic medications
Concurrent use may mask the symptoms of ototoxicity.
Antihistamines may prevent or diminish otherwise positive reaction to dermal reactivity indicators.
Bradycardia; extrasystoles; orthostatic hypotension; palpitations; reflex tachycardia; tachycardia.
Confusion; convulsions; disturbed coordination; dizziness; drowsiness; euphoria; excitation; faintness; fatigue; headache; hysteria; insomnia; irritability; nervousness; neuritis; paresthesias; restlessness; sedation; tremor; vertigo.
Acute labyrinthitis; blurred vision; diplopia; dry nose and throat; nasal stuffiness; sore throat; tinnitus.
Anorexia; constipation; diarrhea; dry mouth; epigastric distress; nausea; vomiting.
Difficult urination; dysuria; early menses; urinary frequency or retention.
Agranulocytosis; hemolytic anemia; thrombocytopenia.
Increased appetite; weight gain.
Chest tightness; respiratory depression; thickening of bronchial secretions; wheezing.
Chills; excessive perspiration; hypersensitivity reactions; photosensitivity.
Assess allergy symptoms (eg, cough, rhinitis, nasal congestion, sneezing, watery eyes, or itching nose, throat, or eyes) before starting therapy and periodically during therapy. Notify health care provider if symptoms are not improving or are getting worse.Dizziness/Drowsiness
Monitor patient for dizziness and excessive drowsiness. If noted, hold therapy and notify health care provider.Review therapy
Ensure therapy periodically is reviewed to determine if it needs to be continued without change or if a dose change (eg, increase, decrease, discontinuation) is indicated.
Category C . Do not use during third trimester.
Contraindicated in breast-feeding mothers.
Overdosage may cause hallucinations, convulsions, and death. Antihistamines may diminish mental alertness. In young children, they may produce paradoxical excitation. Contraindicated in newborn or premature infants. Sustained-release form not recommended in children younger than 12 yr of age.
Use with caution, usually starting at the low end of the dosage range because of the greater frequency of decreased hepatic, renal, or cardiac function, and concomitant diseases or other drug therapy.
May occur. Have epinephrine 1:1,000 immediately available.
Use drug with caution in patients with cirrhosis or other liver disease.
Use drug with caution in patients with predisposition to urinary retention, history of bronchial asthma, increased IOP, hyperthyroidism, CV disease, or hypertension. Avoid in patients with sleep apnea.
Generally not recommended to treat lower respiratory tract symptoms, including asthma.
CNS depression (including sedation, apnea, CV collapse), CNS stimulation (including insomnia, hallucination, tremors, convulsions), tinnitus, blurred vision, dizziness, ataxia, hypotension. Stimulation and atropine-like signs and symptoms (including dry mouth, fixed dilated pupils, flushing, hyperthermia, GI symptoms) are more likely in children.
Copyright © 2009 Wolters Kluwer Health.